Mirum Pharmaceuticals, Inc.

Overview

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for rare and orphan diseases, with an emphasis on conditions with significant unmet medical need. Its stated purpose is to develop patient-inspired therapies and transform treatment for people living with rare diseases.[1]+2

Its marketed portfolio includes LIVMARLI (maralixibat) for cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis; CHOLBAM (cholic acid) for certain bile-acid synthesis and peroxisomal disorders; and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis. Mirum commercializes LIVMARLI directly in the United States, Canada, and certain European countries, and reaches other markets through distributors and licensing partners.[4][5]

As a general indicator of scale, Mirum reported $521.3 million in net product sales for 2025 and $336.1 million for the six months ended June 30, 2026.[6][7] [1]+7

Products & services

Mirum’s marketed products include LIVMARLI (maralixibat), an oral, minimally absorbed ileal bile acid transporter inhibitor for cholestatic pruritus associated with Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It is approved in the U.S., EU and other markets for specified ALGS or PFIC uses; Mirum commercializes it in the U.S., Canada and some European countries, with partners distributing it in additional markets. The product is available as an oral solution and an FDA-approved tablet formulation.[8][9] CHOLBAM (cholic acid) is a capsule approved for pediatric and adult patients with bile-acid synthesis disorders due to single-enzyme defects and as adjunctive treatment for peroxisomal disorders, including Zellweger spectrum disorder. CTEXLI (chenodiol) is a tablet approved for adults with cerebrotendinous xanthomatosis (CTX); it was approved in February 2025.[10]+2

The development portfolio includes volixibat, an oral, minimally absorbed IBAT inhibitor being studied for adult cholestatic liver diseases: its PSC program had reported Phase 2b VISTAS topline results, while its PBC study had completed enrollment, with topline data expected in Q1 2027.[13] A Phase 3 LIVMARLI expansion study in additional rare cholestatic conditions completed enrollment in the first half of 2026, with topline data expected in Q4 2026.[14] MRM-3379, an allosteric PDE4D inhibitor, is in a Phase 2 study for Fragile X syndrome.[15] Brelovitug (BJT-778), a fully human IgG1 antibody that binds hepatitis B surface antigen, is being developed for chronic hepatitis D virus infection in the AZURE clinical program.[16] Zilurgisertib is an oral small-molecule ALK2 inhibitor for fibrodysplasia ossificans progressiva.[17]

For the six months ended June 30, 2026, net product sales were $336.125 million: LIVMARLI accounted for $242.525 million, or approximately 72.2%, and Bile Acid Medicines—CHOLBAM and CTEXLI combined—accounted for $93.600 million, or approximately 27.8%. The reported figures do not separate sales of CHOLBAM from CTEXLI.[18] [8]+13

Geographic presence

Mirum Pharmaceuticals’ operations span the United States and Europe, including the Netherlands, Switzerland, and other European countries. Its principal executive office is in Foster City, California; the company also has an office in Redwood City, California, and offices in Basel and Zug, Switzerland.[19]+3

The United States is a major sales market. For 2025, Livmarli sales were $360.0 million, of which $244.7 million were U.S. sales—about 68% of Livmarli sales. The remainder is an implied non-U.S. balance; the reported figures do not provide a country-by-country or broader regional revenue breakdown.[23]

Outside the United States, Mirum has a commercialization arrangement with Takeda for Livmarli in Japan: Takeda is responsible for development and commercialization for licensed indications, while Mirum supplies the product and receives a percentage of Takeda’s net sales.[24] [19]+5

Business segments

Mirum Pharmaceuticals reports **one operating segment**; it does not report separate operating segments by product or therapeutic area. Its commercial portfolio is presented in two product groups: **Livmarli**, used for cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis, and **Bile Acid Medicines**—Ctexli and Cholbam—for rare bile-acid disorders. Brelovitug, acquired in 2026 and being developed for chronic hepatitis D, is a clinical-stage candidate rather than a separately reported segment or product-sales category.[25]+3

As an approximate measure of the relative contribution of these product groups—not separately reported segments—Livmarli generated **about 69%** of FY2025 net product sales, while Bile Acid Medicines generated **about 31%**. In the six months ended June 30, 2026, the respective shares were **about 72%** and **28%**.[6][18] [25]+7

Company history

Mirum Pharmaceuticals was founded in 2018, with its original Delaware certificate filed on May 2. The company licensed maralixibat from Shire that November, establishing the basis for its first major medicine, later marketed as LIVMARLI.[26][3] Mirum completed its initial public offering on July 22, 2019, selling five million shares at $15 each.[27][28]

A major development milestone came on September 29, 2021, when the FDA approved LIVMARLI for cholestatic pruritus in patients with Alagille syndrome; the company reported its U.S. launch that year.[29][30] The European Commission approved LIVMARLI for the same condition in December 2022.[31] In August 2023, Mirum completed its acquisition of Travere Therapeutics’ bile-acid medicines portfolio, including CHOLBAM and CHENODAL.[32] LIVMARLI received FDA approval for cholestatic pruritus in patients with progressive familial intrahepatic cholestasis in 2024, and the FDA approved CTEXLI (chenodiol) for adults with cerebrotendinous xanthomatosis in February 2025.[33][34] In January 2026, Mirum completed its acquisition of Bluejay Therapeutics, adding the investigational medicine brelovitug to its portfolio.[35] [27]+10

Sources

• Mirum Pharmaceuticals, Inc. — Full financial report (2025 Y)
  10 citations

  [1][2][4][5][6][19][20][21][22][32]
• mirumpharma.com[3]
• Mirum Pharmaceuticals, Inc. — Press release (2026 Q 2)[7]
• Mirum Pharmaceuticals, Inc. — Full financial report (2026 Q 2)
  12 citations

  [8][10][11][12][13][14][15][16][17][18][24][25]
• ir.mirumpharma.com[9]
• ir.mirumpharma.com[23]
• www.sec.gov[26]
• Mirum Pharmaceuticals, Inc. — Full financial report (2019 Y)[27][28]
• www.businesswire.com[29]
• ir.mirumpharma.com[30]
• ir.mirumpharma.com[31]
• ir.mirumpharma.com[33]
• ir.mirumpharma.com[34]
• Mirum Pharmaceuticals, Inc. — Full financial report (2026 Q 1)[35]